Sponsors should be aware of the significant implications the Addendum is likely to have on clinical trial planning, conduct, statistical analysis, and interpretation.
Ülker Aydemir
Advertisement
Articles by Ülker Aydemir
Advertisement
Latest Updated Articles
- Estimands and Implications for Sponsors as ICH E9 (R1) Addendum Progresses
Published: December 13th 2017 | Updated:
Advertisement
Advertisement
Trending on Applied Clinical Trials Online
1
Honing the Power of AI for Next Generation Trial Oversight and Execution
2
ACT Brief: AI-Driven Oversight, Biotech Acceleration Strategies, and a Major Win in Bladder Cancer
3
A Look Back: AI and Pragmatic Trials Took Center Stage at SCOPE Summit 2025
4
.png "BioPharm International")
.png "Pharmaceutical Commerce"){kind=logo}
.png "Turbo Machinery Magazine")
.png){kind=spacer}
